Search Results
Apr 29, 2026, 16:05 ET Neurocrine Biosciences Announces Publication Establishing Clinically Meaningful Improvement Threshold for the Tardive Dyskinesia Impact Scale
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the publication of new peer-reviewed research in
More news about: Neurocrine Biosciences, Inc.
Apr 22, 2026, 16:05 ET Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Showing Sustained Glucocorticoid Dose Reductions While Maintaining Androgen Control in Adults with Classic Congenital Adrenal Hyperplasia
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the first presentation of new two-year data from the Phase 3 CAHtalyst® Adult study demonstrating sustained, substantial
More news about: Neurocrine Biosciences, Inc.
Apr 14, 2026, 16:01 ET Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2026 Financial Results
SAN DIEGO, April 14, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its first quarter 2026 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m. Eastern
More news about: Neurocrine Biosciences, Inc.
Apr 14, 2026, 08:30 ET Neurocrine Biosciences Presents First Real-World Head-to-Head Claims Analysis Demonstrating Greater Treatment Persistence with INGREZZA® (valbenazine) Capsules Compared to AUSTEDO XR
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of new real-world evidence demonstrating that adult patients with tardive dyskinesia receiving
More news about: Neurocrine Biosciences, Inc.
Apr 06, 2026, 07:00 ET Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio
SAN DIEGO and REDWOOD CITY, Calif., April 6, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) and Soleno Therapeutics, Inc. (Nasdaq: SLNO) today announced that Neurocrine has entered into a definitive agreement to acquire Soleno for $53.00 per
More news about: Neurocrine Biosciences, Inc.
Mar 26, 2026, 08:30 ET Neurocrine Biosciences Presents First Expert Consensus Recommendations for Tardive Dyskinesia in Long-Term Care Settings
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of the first expert consensus recommendations focused on screening, diagnosis and treatment of tardive dyskinesia among
More news about: Neurocrine Biosciences, Inc.
Mar 17, 2026, 16:05 ET Neurocrine Biosciences Appoints Andrew Ratz, Ph.D., as Chief Technical Operations Officer
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the promotion of Andrew Ratz, Ph.D., to the executive management team as the Chief Technical Operations Officer. In his new role, Dr.
More news about: Neurocrine Biosciences, Inc.
Mar 10, 2026, 16:01 ET Neurocrine Biosciences to Present at the Stifel 2026 Virtual CNS Forum
SAN DIEGO, March 10, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that members of the management team will participate at the Stifel 2026 Virtual CNS Forum at 4:30 PM EST on March 17, 2026.
More news about: Neurocrine Biosciences, Inc.
Mar 06, 2026, 17:00 ET BetterInvesting™ Magazine Update on Equifax Inc. (NYSE: EFX) and Neurocrine Bio In. (NASDAQ: NBIX)
Neurocrine Bio In. (NASDAQ: NBIX), which the independent Editorial Advisory and Securities Review Committee believes is worthy of further study from an undervalued perspective. Committee
More news about: NAIC-BetterInvesting
Feb 24, 2026, 16:01 ET Neurocrine Biosciences to Present at Upcoming Investor Conferences in March
SAN DIEGO, Feb. 24, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that members of the management team will participate at the following investor conferences:
More news about: Neurocrine Biosciences, Inc.
Feb 11, 2026, 16:01 ET Neurocrine Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Financial Expectations for 2026
SAN DIEGO, Feb. 11, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the fourth quarter ended December 31, 2025.
More news about: Neurocrine Biosciences, Inc.
Jan 26, 2026, 08:30 ET Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive Dyskinesia
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 2 clinical study of investigational compound NBI-1065890 in adults with tardive dyskinesia (TD). NBI-1065890
More news about: Neurocrine Biosciences, Inc.
Jan 21, 2026, 16:01 ET Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2025 Financial Results
SAN DIEGO, Jan. 21, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its fourth quarter and year-end 2025 financial results conference call and webcast for 1:30 p.m. Pacific Time
More news about: Neurocrine Biosciences, Inc.
Jan 15, 2026, 08:30 ET Neurocrine Biosciences Presents Head-to-Head INGREZZA® (valbenazine) Capsules Data Demonstrating Higher VMAT2 Target Occupancy Compared to AUSTEDO XR
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of the first head-to-head data comparing vesicular monoamine transporter 2 (VMAT2) target occupancy between
More news about: Neurocrine Biosciences, Inc.
Jan 05, 2026, 16:01 ET Neurocrine Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Jan. 5, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the 44th Annual J.P. Morgan Healthcare Conference at 9:45 a.m. Pacific Time on Monday, January 12, 2026, in San Francisco.
More news about: Neurocrine Biosciences, Inc.
Dec 22, 2025, 16:05 ET Neurocrine Biosciences Provides Update on Phase 3 Study of Valbenazine in Dyskinetic Cerebral Palsy
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Phase 3 KINECT®-DCP study evaluating the efficacy, safety, and tolerability of valbenazine in pediatric and adult
More news about: Neurocrine Biosciences, Inc.
Dec 16, 2025, 16:01 ET Neurocrine Biosciences Showcases R&D Transformation Driving Innovation Across Neuroscience and Endocrinology
SAN DIEGO, Dec. 16, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced a new chapter in its research and development strategy, designed to fuel the Company's next era for growth and deliver long-term value.
More news about: Neurocrine Biosciences, Inc.
Dec 09, 2025, 16:01 ET Neurocrine Biosciences to Host R&D Day on December 16
SAN DIEGO, Dec. 9, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will hold its 2025 R&D Day on Tuesday, December 16, 2025, at 12:00 p.m. Eastern Time (9:00 a.m. Pacific Time) in San Diego.
More news about: Neurocrine Biosciences, Inc.
Nov 20, 2025, 08:30 ET Neurocrine Biosciences Announces Publication of Landmark Narrative Review on FDA-Approved VMAT2 Inhibitors Demonstrating Unique Profile of INGREZZA® (valbenazine) Capsules
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the publication of a comprehensive peer-reviewed narrative review that consolidates pharmacologic, pharmacokinetic and more than a decade
More news about: Neurocrine Biosciences, Inc.
Nov 11, 2025, 16:01 ET Neurocrine Biosciences to Present at Upcoming Investor Conferences
SAN DIEGO, Nov. 11, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that members of the management team will participate at the following investor conferences:
More news about: Neurocrine Biosciences, Inc.
Nov 10, 2025, 16:05 ET Neurocrine Biosciences Provides Update on Phase 2 Study of NBI-1070770 in Adults with Major Depressive Disorder
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Phase 2 study evaluating the efficacy, safety and tolerability of investigational compound NBI-1070770 in adults with major
More news about: Neurocrine Biosciences, Inc.
Oct 28, 2025, 16:01 ET Neurocrine Biosciences Reports Third Quarter 2025 Financial Results
SAN DIEGO, Oct. 28, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the third quarter ended September 30, 2025.
More news about: Neurocrine Biosciences, Inc.
Oct 17, 2025, 08:30 ET Neurocrine Biosciences Presents New KINECT® 4 Post-Hoc Analysis Demonstrating Rapid and Sustained Therapeutic Efficacy of INGREZZA® (valbenazine) 40 mg Capsules
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of a new post-hoc analysis from the Phase 3, open-label KINECT® 4 study, demonstrating that patients treated
More news about: Neurocrine Biosciences, Inc.
Oct 07, 2025, 16:01 ET Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2025 Financial Results
SAN DIEGO, Oct. 7, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its third quarter 2025 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m. Eastern
More news about: Neurocrine Biosciences, Inc.
Oct 06, 2025, 16:05 ET Neurocrine Biosciences Appoints Mike Sibley as Senior Vice President, General Manager of Neuropsychiatry Franchise
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of Mike Sibley as Senior Vice President and General Manager of the company's Neuropsychiatry franchise. Sibley, a proven
More news about: Neurocrine Biosciences, Inc.